SHESTCO to bridge research gap via Technology
By Olasunkanmi Onifade
The Sheda Science and Technology Complex (SHESTCO) has expressed its commitment to bridging the gap in research and development through technology.
The Director-General of SHESTCO, Prof. Paul Onyenekwe, made this assertion on Wednesday during SHESTCO Day at the ongoing Science, Technology, and Innovation Expo in Abuja.
He stated that the complex was a leading hub for research utilising modern technology, emphasising that it had acquired new equipment ready for researchers’ use.
“We are extending an invitation to scientists and researchers with proposals involving modern equipment; much of this equipment is not commonly found in most institutions, but we have it available.
“Our facilities are open for use,” Onyenekwe emphasised.
According to him, the complex offers opportunities for institutions of higher learning in the country to conduct capital-intensive research at a cost-effective rate.
Onyenekwe added that the complex also facilitated the development of advanced computational and multiscale modeling and simulation foundations, along with establishing a resource-based center to accelerate scientific discovery in the country.
He further mentioned that the complex had already constructed three zonal offices across the country and planned to build offices in Kano, Anambra, and Plateau.
In addition, Andrew Iloh, the Director of the Biotechnology Advanced Research Centre at SHESTCO, stated that the biotechnology research center had successfully trained over 1000 industrial training students and approximately 100 masters and PhDs in various research fields.
“We aim for our research to attain innovative status; we want our research outcomes to contribute to the country’s economic growth.
“Biotechnology offers an excellent opportunity to build a sustainable economy,” he remarked.
Prof. Danlami Uzama, the Director of the Chemistry Advanced Research Centre at SHESTCO, disclosed that the complex had developed an anti-sickening phytodrug derived from local plants.
He explained that the phytodrug had undergone compounding and toxicology studies, with preclinical studies indicating its effectiveness as an anti-sickling drug.
Furthermore, he highlighted that the complex had developed an anti-epilepsy phytodrug currently undergoing phases 1 and 2 clinical trials. (NAN)
Edited by Maureen Ojinaka/Deji Abdulwahab
Published By
Has also recently published
GenderNovember 8, 2024WIMBIZ, stakeholders urge women to dream big, challenge stereotypes
HealthNovember 8, 2024Nigeria, 7 others begin African-led HIV vaccine initiative
HealthNovember 7, 2024FG, Chinese firm partner on local HIV test kits
Economy/BusinessNovember 5, 2024Asset tracking, valuation, crucial for accountability -AGF
